Princess Maxima Center For Pediatric Oncology

This study tests a combination of two chemotherapy drugs (Vyxeos and clofarabine) in children and young adults up to age 21 whose acute myeloid leukemia (AML) has come back or not responded to standard treatment. The goal is to find the safest dose and see if the combination can …

This study tests a combination of two targeted drugs (dasatinib and venetoclax) plus chemotherapy in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to standard treatment. The goal is to find the best dose and see if the combo can s…

This study tests a combination of the targeted drug trametinib with standard chemotherapy drugs in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to treatment. The goal is to find the safest dose and see if the combination can shri…

This study tests a combination of two targeted drugs (ruxolitinib and venetoclax) plus standard chemotherapy in children and young adults with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoma. The goal is to find the safest dose and see how well the treatment sh…

This study tests a drug called blinatumomab in infants under 1 year old who have a specific, hard-to-treat type of leukemia (KMT2A-rearranged). The goal is to improve how long these babies stay cancer-free and to help them live longer. About 160 infants will take part, and the tr…

This study tests a drug called brigatinib in children and young adults (ages 1 to 25) with certain cancers that have an ALK gene change. The goal is to find the best dose and see if the drug is safe and works against these tumors. About 65 participants will take brigatinib pills,…

This study creates a team of experts across Europe to help doctors pick the best available treatment for children and young adults whose blood cancer has come back or not responded to therapy. By analyzing each patient's unique tumor markers, the team gives personalized advice on…